MX2022014375A - Anticuerpo anti-cd20 quimerico canino. - Google Patents

Anticuerpo anti-cd20 quimerico canino.

Info

Publication number
MX2022014375A
MX2022014375A MX2022014375A MX2022014375A MX2022014375A MX 2022014375 A MX2022014375 A MX 2022014375A MX 2022014375 A MX2022014375 A MX 2022014375A MX 2022014375 A MX2022014375 A MX 2022014375A MX 2022014375 A MX2022014375 A MX 2022014375A
Authority
MX
Mexico
Prior art keywords
antibody
canine anti
chimeric canine
chimeric
hodgkins
Prior art date
Application number
MX2022014375A
Other languages
English (en)
Inventor
James David Pancook
Original Assignee
Elanco Us Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elanco Us Inc filed Critical Elanco Us Inc
Publication of MX2022014375A publication Critical patent/MX2022014375A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a anticuerpos anti-CD20 quiméricos caninizados para la proteína canina CD20 y a métodos de uso para tratar ciertos trastornos tales como el linfoma de células B no Hodgkins en perros.
MX2022014375A 2016-02-18 2018-08-16 Anticuerpo anti-cd20 quimerico canino. MX2022014375A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662296729P 2016-02-18 2016-02-18

Publications (1)

Publication Number Publication Date
MX2022014375A true MX2022014375A (es) 2022-12-15

Family

ID=58098709

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018009955A MX2018009955A (es) 2016-02-18 2017-02-10 Anticuerpo anti-cd20 quimerico canino.
MX2022014375A MX2022014375A (es) 2016-02-18 2018-08-16 Anticuerpo anti-cd20 quimerico canino.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018009955A MX2018009955A (es) 2016-02-18 2017-02-10 Anticuerpo anti-cd20 quimerico canino.

Country Status (14)

Country Link
US (4) US10519244B2 (es)
EP (1) EP3416984B1 (es)
JP (1) JP6661019B2 (es)
KR (1) KR102131544B1 (es)
CN (1) CN108699152B (es)
AU (1) AU2017219596B2 (es)
BR (1) BR112018016367A2 (es)
CA (1) CA3014461C (es)
DK (1) DK3416984T3 (es)
EA (1) EA039434B1 (es)
ES (1) ES2868650T3 (es)
MX (2) MX2018009955A (es)
NZ (1) NZ744192A (es)
WO (1) WO2017142800A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108699152B (zh) * 2016-02-18 2022-08-19 伊兰科美国公司 嵌合犬抗cd20抗体
US20200362034A1 (en) * 2017-08-15 2020-11-19 Kindred Biosciences, Inc. IgG Fc Variants for Veterinary Use
JP2021059499A (ja) 2019-10-03 2021-04-15 日本全薬工業株式会社 イヌｃｄ２０に対するモノクローナル抗体又は抗体フラグメント
KR20240021959A (ko) * 2021-06-17 2024-02-19 펫메딕스 리미티드 항개 cd20 항체
WO2023010057A1 (en) * 2021-07-28 2023-02-02 Atreca, Inc. Atrc-101 target expression assay

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101914158A (zh) * 2002-02-14 2010-12-15 免疫医疗公司 抗cd 20抗体及其融合蛋白和使用方法
JP4745242B2 (ja) * 2003-05-20 2011-08-10 アプライド モレキュラー エボリューション，インコーポレイテッド Ｃｄ２０結合分子
AR044388A1 (es) * 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
BRPI0819593A2 (pt) * 2007-12-21 2015-05-05 Genentech Inc "método para tratamento de um paciente com artrite reumatóide (ra)"
US8569460B2 (en) * 2009-03-25 2013-10-29 Vet Therapeutics, Inc. Antibody constant domain regions and uses thereof
WO2011057188A1 (en) * 2009-11-06 2011-05-12 Idexx Laboratories, Inc. Canine anti-cd20 antibodies
AU2011221553B2 (en) 2010-03-04 2016-05-26 Vet Therapeutics Inc. Monoclonal antibodies directed to CD20
GB201114858D0 (en) * 2011-08-29 2011-10-12 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of using the same
EP2766391A1 (en) 2011-10-13 2014-08-20 NVIP Pty Ltd Canine/feline cd20 binding epitope and compositions for binding thereto
WO2013063186A2 (en) * 2011-10-26 2013-05-02 Novartis Animal Health Us, Inc. Monoclonal antibodies and methods of use
WO2016016859A1 (en) * 2014-07-31 2016-02-04 Amgen Research (Munich) Gmbh Optimized cross-species specific bispecific single chain antibody constructs
CN108699152B (zh) * 2016-02-18 2022-08-19 伊兰科美国公司 嵌合犬抗cd20抗体

Also Published As

Publication number Publication date
BR112018016367A2 (pt) 2019-01-22
US20200131273A1 (en) 2020-04-30
ES2868650T3 (es) 2021-10-21
DK3416984T3 (da) 2021-04-26
AU2017219596B2 (en) 2019-07-04
AU2017219596A1 (en) 2018-07-19
NZ744192A (en) 2019-11-29
US20210163618A1 (en) 2021-06-03
EP3416984B1 (en) 2021-03-31
KR102131544B1 (ko) 2020-07-07
EA039434B1 (ru) 2022-01-27
KR20180096804A (ko) 2018-08-29
WO2017142800A1 (en) 2017-08-24
US20230257476A1 (en) 2023-08-17
JP6661019B2 (ja) 2020-03-11
JP2019507128A (ja) 2019-03-14
EA201891499A1 (ru) 2019-01-31
MX2018009955A (es) 2018-11-29
US10941206B2 (en) 2021-03-09
CA3014461A1 (en) 2017-08-24
US10519244B2 (en) 2019-12-31
CA3014461C (en) 2023-02-28
US20190194342A1 (en) 2019-06-27
CN108699152B (zh) 2022-08-19
CN108699152A (zh) 2018-10-23
EP3416984A1 (en) 2018-12-26

Similar Documents

Publication Publication Date Title
MX2022014375A (es) Anticuerpo anti-cd20 quimerico canino.
PH12017501521A1 (en) Anti-dll3 chimeric antigen receptors and methods of use
MX2017008875A (es) Anticuerpos biespecificos contra cd3 y cd20.
MX2022006568A (es) Agentes anti-cd20, agentes anti-cd22, y usos y combinaciones de los mismos con una celula que expresa un receptor de antigeno quimerico (car) de cd19.
PH12017501127A1 (en) Antibodies targeting b-cell maturation antigen and methods of use
PH12017500322A1 (en) Anti-her2 antibodies and immunoconjugates
SA517381703B1 (ar) C10orf54 - أجسام مضادة لـ واستخداماتها
PH12017501039A1 (en) Antibodies targeting g-protein coupled receptor and methods of use
PH12016501908A1 (en) Bispecific antibodies that bind to cd38 and cd3
EA201791093A1 (ru) Антитела к cd47, способы и применение
NZ731467A (en) Anti-tim3 antibodies and methods of use
PH12018500710A1 (en) Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
NZ731782A (en) Pyrrolobenzodiazepine-antibody conjugates
PH12017500825A1 (en) Anti-cldn chimeric antigen receptors and methods of use
WO2013063186A3 (en) Monoclonal antibodies and methods of use
MX2017007097A (es) Combinacion de anticuerpos anti-cs1 y anti-muerte programada 1 (pd1) para tratar cancer (mieloma).
MA40536A (fr) Anticorps anti-alpha v bêta 5 humanisés et leurs utilisations
UA105682U (uk) Препарат "кватронан-se" для стимуляції заплідненості корів